Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM)
Year: 2018
Type: conference-abstract
Source: Blood
Institutions: Stanford Medicine, Stanford University, Guy's and St Thomas' NHS Foundation Trust, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Beatson West of Scotland Cancer Centre, University of Glasgow, University of Pennsylvania, University of Colorado Hospital, University of Colorado Denver, Blueprint Medicines (United States), University of Utah, Huntsman Cancer Institute
Language: English
Topic: Mast cells and histamine
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2907852271